Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan-Reference-Cited by-同舟云学术

Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan

Published:2022-01-24 Issue:1 Volume:27 Page:157-166
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Baba Terumi¹,Hashimoto Yoshinori¹²³,Yasuda Hajime¹,Araki Marito²³⁴,Edahiro Yoko¹²³,Morishita Soji²³,Ochiai Tomonori¹²³,Shirane Shuichi¹²³,Ando Jun¹⁴,Komatsu Norio¹²³

Affiliation:

1. Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan

2. Laboratory for the Development of Therapies Against MPN, Juntendo University Graduate School of Medicine, Tokyo, Japan

3. Department of Advanced Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan

4. Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology

MEXT’s Promotion Plan for the Platform of Human Resource Development for Cancer Project

Japan Society for the Promotion of Science

Takeda Science Foundation

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.2022848

Reference28 articles.

1. A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders

2. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

3. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

4. SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2

5. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myocardial infarction as the initial presentation of essential thrombocytosis in a young patient;Cardiovascular Revascularization Medicine: Interesting Cases;2024-03

2. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera;Physiology International;2023-09-05

3. Prognostication in myeloproliferative neoplasms, including mutational abnormalities;Blood Research;2023-03-16

4. Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study;Journal of Thrombosis and Thrombolysis;2023-01-18